Each immune test or product-quality check answers a particular question. Connecting those questions helps explain how a proposed treatment moves from molecular measurements to evidence in people.
This reading map links immune-assay readouts, antigen evidence, specimen preparation, RNA design, recognition modules and product quality. It is a set of evidence questions, not a required experimental sequence. Receptor binding, cytokine release, cell killing, lot potency and clinical benefit are different observations. A useful explanation names the sample, assay, model and comparison that support the claim, including the steps that remain untested.
Shares RNA integrity and assay suitability, Finite tissue and specimen allocation, Specimen provenance and derivative tracking, Peripheral blood mononuclear cell specimens.
Shares Certificate of analysis, Comparability after manufacturing changes, Chemistry, manufacturing and controls, Immune-cell cytotoxicity assays.
Shares Immunodominance, Binder affinity, epitope and developability, Binders as targeting modules, Neoantigen.
Shares Intracellular cytokine staining, Peptide-HLA multimer staining, Peripheral blood mononuclear cell specimens, Immune-cell cytotoxicity assays.
Shares Cell segmentation in tissue measurements, Targeted proteomics and quantification limits, Tissue preparation and assay suitability.
Shares Certificate of analysis, Comparability after manufacturing changes, Chemistry, manufacturing and controls.
Shares Immunopeptidome, Self-similarity and immune-recognition specificity, Immunopeptidomics, Immunogenicity and clinical efficacy.
Shares Modified nucleosides in messenger RNA, Messenger RNA construct anatomy, Chemistry, manufacturing and controls.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/